Lead researcher:Dr Anne Lanceley
Location: University College London
Research strand: Support
This research was a large, international study to assess whether, for women with advanced ovarian cancer, the symptoms benefit of continuing with chemotherapy can be assessed so women can make an informed choice about continuing with further rounds of chemotherapy.
Women with advanced ovarian cancer often experience symptoms that significantly limit their quality of life, and usually receive palliative chemotherapy to alleviate these symptoms. However side effects from chemotherapy can also reduce quality of life.
Traditional methods of measuring chemotherapy response for this group do not reflect how women’s symptoms benefit from treatments that are often given near the end of life. This study aimed to predict who would benefit from chemotherapy, so as to avoid unnecessary treatment.
The measures will help women make informed treatment decisions at a point in their illness where quality of life may be at least as important as survival time. The measures will also be useful in clinical trials to evaluate future treatments.
Very few research projects in palliative care are funded, arising from very little attention in this area, which is so essential. Without Target Ovarian Cancer’s funding, women in the UK would not have participated in this critical global study, which involved over 900 women from 23 countries.
This project funding is now completed.
- Read about advanced ovarian cancer
- Download Looking after me, our guide for women if they have been told that their ovarian cancer is terminal
- Fund our research